Kowa Company, Ltd.
Quick facts
Phase 3 pipeline
- K-924 HD · Cardiovascular
K-924 HD is a selective aldosterone antagonist that blocks mineralocorticoid receptor signaling to reduce sodium retention and blood pressure. - K-924 LD · Neurology
K-924 LD is a long-acting dopamine D2/D3 receptor agonist designed to provide sustained dopaminergic activity for extended treatment intervals. - NIK-333(peretinoin) · Oncology
NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Kowa Company, Ltd.
What is Kowa Company, Ltd.'s pipeline?
Kowa Company, Ltd. has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include K-924 HD, K-924 LD, NIK-333(peretinoin).
Related
- Sector hub: All tracked pharma companies